The VTGN chart now looks iffy based on today's close, so it's back to watch mode since a test of .50 now looks likely. Odds are increasing that this one could go lower.
They have clinical date due by late summer, but the bad data from last week in a related trial has likely poisoned the well and a rebound looks difficult.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.